Director Mark F. Lindsay of Vivos Therapeutics, Inc. filed a Form 4 on October 26, 2026, disclosing a grant of 12,000 stock options received on September 14, 2026.

Key Highlights

  • Grant date: Mark F. Lindsay received 12,000 stock options on September 14, 2026, with an exercise price of $0.18 per share.
  • Vesting schedule: One-half vested immediately on the grant date, one-fourth will vest on September 30, 2026, and one-fourth will vest on December 31, 2026, according to the filing.
  • Option term: The options are exercisable for a period of 10 years from the grant date, expiring on September 14, 2036.
  • Price of derivative security: The filing reports the price of the derivative security as $0.
  • Post-transaction holdings: Following the grant, Lindsay beneficially owns 17,200 derivative securities (stock options) directly.
  • Prior expirations: The filing notes that 667 options expired unexercised on June 19, 2025, and 1,200 options expired unexercised on August 5, 2026.

Mark F. Lindsay's September 2026 Option Grant at Vivos Therapeutics

According to the Form 4 filed with the SEC on October 26, 2026, Mark F. Lindsay, a director of Vivos Therapeutics, Inc. (NASDAQ:VVOS), received a grant of 12,000 stock options on September 14, 2026. The options carry an exercise price of $0.18 and are classified as Stock Options (Right to Buy) covering shares of common stock. The filing was signed by Bradford K. Amman as attorney-in-fact for Mark F. Lindsay.

The filing details a split vesting schedule: one-half of the options vested immediately on the grant date, one-fourth are set to vest on September 30, 2026, and the remaining one-fourth on December 31, 2026. The options have a term of 10 years from the grant date, with an expiration date of September 14, 2036. The transaction code is listed as "A," indicating an acquisition.

The filing also discloses that 667 options expired unexercised on June 19, 2025, and 1,200 options expired unexercised on August 5, 2026. After accounting for the new grant and those prior expirations, Lindsay's total beneficial ownership of derivative securities stands at 17,200 stock options, held directly. No non-derivative securities transactions were reported in Table I of this filing.

What Was Disclosed

Director Mark F. Lindsay disclosed the acquisition of 12,000 stock options in Vivos Therapeutics, Inc. at an exercise price of $0.18, granted September 14, 2026, with a split vesting schedule and a 10-year exercise term, resulting in total beneficial ownership of 17,200 stock options.